Cadonilimab
id:
cadonilimab-261-2416447
title:
Cadonilimab
text:
Cadonilimab is a PD-1/CTLA-4 bispecific monoclonal antibody developed to treat a variety of solid cancer types. In June 2022 it was approved in China "for use in patients with relapsed or metastatic cervical cancer (r/mCC) who have progressed on or after platinum-based chemotherapy".
brand slug:
wiki
category slug:
encyclopedia
description:
Monoclonal antibody
original url:
https://en.wikipedia.org/wiki/Cadonilimab
date created:
date modified:
2024-04-24T19:57:28Z
main entity:
{"identifier":"Q123585479","url":"https://www.wikidata.org/entity/Q123585479"}
image:
fields total:
13
integrity:
14